Last viewed:
CFRX
Prices are updated after-hours
CFRX
|
$0.05
0.0%
910K
|
Health Technology
(0.0% 1d)
(0.0% 1m)
(-97.5% 1y)
(0.0% 2d)
(0.0% 3d)
(0.0% 7d)
(2396.14%
volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 535,240
http://www.contrafect.com
Sec
Filling
|
Patents
| 24 employees
(US) ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
antibody
monoclonal antibodies
infectious disease
influenza
treatment
bloodstream
injection
add to watch list
Paper trade
email alert is off
Press-releases
Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology, Corp.’; Athersys, Inc.; Borqs Technologies, Inc.; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition Corp.; Evelo Biosciences, Inc.; Troika Media Group, Inc.; Impel Pharmaceuticals Inc.; Fresh Tracks Therapeutics, Inc.; and Near Intelligence, Inc. from The Nasdaq Stock Market
Published: 2023-12-26
(Crawled : 21:00)
- globenewswire.com
SDCCQ
|
$0.0025
-20.0%
150K
|
n/a
| -50.0%
| O: -28.75%
H: 40.35%
C: 15.79%
NDAQ
|
$60.35
0.47%
0.46%
3.1M
|
Finance
| 4.13%
| O: -0.07%
H: 0.75%
C: 0.69%
CWBR
|
$0.9003
-11.88%
360
|
Health Technology
| 11.19%
| O: 0.0%
H: 5.11%
C: 5.11%
nasdaq
media
acquisition
pharmaceuticals
market
Global Antibiotic Resistance Market Research Report 2023-2027: Search for Alternatives to Antibiotics Creates New Goldrush
Published: 2023-10-27
(Crawled : 15:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -11.93%
| O: -18.18%
H: 0.0%
C: 0.0%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
| -4.46%
| O: -2.35%
H: 0.0%
C: 0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -14.36%
| O: -15.73%
H: 0.0%
C: 0.0%
ENTA
|
$13.28
0.38%
0.38%
140K
|
Health Technology
| 74.35%
| O: -0.36%
H: 1.07%
C: -0.71%
CFRX
|
$0.05
0.0%
910K
|
Health Technology
| -83.06%
| O: -0.41%
H: 2.04%
C: -7.79%
ARDS
|
$0.0615
2.82%
410K
|
Health Technology
| -25.93%
| O: 16.05%
H: 1.06%
C: -7.98%
report
antibiotics
research
global
market
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyCF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial
Published: 2023-10-16
(Crawled : 19:00)
- biospace.com/
CFRX
|
$0.05
0.0%
910K
|
Health Technology
| -91.21%
| O: 17.89%
H: 0.0%
C: -29.19%
cf-370
fda
clearance
application
trial
pathogens
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
Published: 2023-09-19
(Crawled : 12:00)
- globenewswire.com
CFRX
|
$0.05
0.0%
910K
|
Health Technology
| -92.31%
| O: -9.23%
H: 1.69%
C: -3.73%
drug
conference
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
Published: 2023-09-18
(Crawled : 12:00)
- globenewswire.com
CFRX
|
$0.05
0.0%
910K
|
Health Technology
| -91.1%
| O: 15.66%
H: 0.0%
C: 0.0%
cf-370
fda
candidate
application
submission
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
Published: 2023-08-28
(Crawled : 12:00)
- globenewswire.com
CFRX
|
$0.05
0.0%
910K
|
Health Technology
| -93.33%
| O: -0.01%
H: 0.0%
C: -4.25%
world
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
Published: 2023-08-14
(Crawled : 12:20)
- globenewswire.com
CFRX
|
$0.05
0.0%
910K
|
Health Technology
| -94.76%
| O: 4.71%
H: 0.0%
C: -4.01%
business
update
financial
results
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
Published: 2023-06-27
(Crawled : 12:20)
- globenewswire.com
CFRX
|
$0.05
0.0%
910K
|
Health Technology
| -96.3%
| O: -3.7%
H: 13.08%
C: 11.54%
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens
Published: 2023-06-20
(Crawled : 13:00)
- globenewswire.com
CFRX
|
$0.05
0.0%
910K
|
Health Technology
| -97.19%
| O: 1.69%
H: 2.76%
C: -5.52%
pathogens
platform
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023
Published: 2023-06-08
(Crawled : 20:00)
- globenewswire.com
CFRX
|
$0.05
0.0%
910K
|
Health Technology
| -96.53%
| O: 25.0%
H: 22.78%
C: 7.78%
pathogens
potential
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount